David Cheng
Hematology & Oncology · Fremont, CANPI 1104892652
Payments from drug & device makers
Across 529 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$2K
- Novo Nordisk$1K
- AstraZeneca$803
- Amgen$669
- Gilead$583
- Johnson & Johnson$576
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,383100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 108 | $1,625 |
| Novo Nordisk | 77 | $1,066 |
| AstraZeneca(2 entities) | 42 | $803 |
| Amgen | 28 | $669 |
| Gilead | 39 | $583 |
| Johnson & Johnson(2 entities) | 28 | $576 |
| Lilly USA, LLC | 28 | $544 |
| Boehringer Ingelheim | 27 | $526 |
| GSK | 23 | $436 |
| Seagen Inc. | 15 | $388 |
| Pfizer | 14 | $355 |
| Bayer | 27 | $320 |
| Merck | 8 | $176 |
| Esperion Therapeutics, Inc. | 7 | $154 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $129 |
| Novartis | 6 | $117 |
| Ironwood Pharmaceuticals, Inc | 5 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| Epizyme, Inc. | 6 | $94 |
| Sanofi | 4 | $91 |
| EMD Serono, Inc. | 3 | $60 |
| Genentech USA, Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $47 |
| IBSA Pharma Inc. | 2 | $43 |
| Eisai Inc. | 2 | $31 |
| Radius Health, Inc. | 1 | $27 |
| AbbVie | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Dova Pharmaceuticals | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Mylan Institutional Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$9,392 in reported general payments places this provider in the 50th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 18 | $54 |
| Famotidine | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Fremont
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.